Company

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease
HKG: 1877Junshi Biosciences

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877; SHA: 688180) announced a dual regulatory advance for its PD‑1 inhibitor toripalimab (brand name: Loqtorzi, product code: JS001): the indication for locally advanced…

Eli Lilly's Retatrutide Beats Ozempic Head‑to‑Head in Phase 3 TRANSCEND-T2D-2 – Greater A1C Reduction and Roughly Double the Weight Loss in Type 2 Diabetes

Eli Lilly’s Retatrutide Beats Ozempic Head‑to‑Head in Phase 3 TRANSCEND-T2D-2 – Greater A1C Reduction and Roughly Double the Weight Loss in Type 2 Diabetes

HutchMed's Sovleplenib Granted FDA Orphan Drug Designation for Primary Immune Thrombocytopenia – Selective Syk Inhibitor Broadens Global Regulatory Footprint

HutchMed’s Sovleplenib Granted FDA Orphan Drug Designation for Primary Immune Thrombocytopenia – Selective Syk Inhibitor Broadens Global Regulatory Footprint

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
IASO Biotherapeutics & Cellbri Sign Global Cell‑Therapy Alliance
Cell-therapyCellbri Bio

IASO Biotherapeutics & Cellbri Sign Global Cell‑Therapy Alliance

Qilu Pharmaceutical Commences Phase III Trial of QLS31905 for Advanced Pancreatic Cancer
Clinical trial approval / initiationMulti-specific antibodies

Qilu Pharmaceutical Commences Phase III Trial of QLS31905 for Advanced Pancreatic Cancer

Novartis Expands Iptacopan Approval to IgA Nephropathy in China
NovartisNYSE: NVS

Novartis Expands Iptacopan Approval to IgA Nephropathy in China

Sihuan Pharma Secures IND for Dual‑Target GLP‑1/GCGR Drug P052 Injection
Clinical trial approval / initiationDiabetes

Sihuan Pharma Secures IND for Dual‑Target GLP‑1/GCGR Drug P052 Injection

Show More